UNSPSC 51393319: Difeterol hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C25H29NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H9ZL6T9U7J, chemically known as benzenemethanol, .alpha.-(1-((2-(diphenylmethoxy)ethyl)methylamino)ethyl)-, hydrochloride (1:1), but more generally known as difeterol hydrochloride, which bears US NIH Compound Identifier 444032.

European Medicines Agency schedules difeterol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07125MIG. Most nations, for tariff purposes, schedule difeterol hydrochloride under HS 29221980. SMILES: CC(C(C1CCCCC1)O)N(C)CCOC(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51393319 Difeterol hydrochloride is a Commodity code that nominally identifies a specific pharmaceutical compound, but recent state and local procurement activity under this code shows little alignment with that narrow scope. The two recent opportunities posted under the code are substantially unrelated to difeterol hydrochloride itself: one solicits naloxone and drug deactivation systems, the other seeks vendor capacity information for a direct-to-manufacturer prescription program. The code's current tagging by state and local issuers does not reflect a coherent purchasing pattern around the pharmaceutical itself, suggesting either misclassification in the opportunities or a fundamental mismatch between the code's intended scope and actual procurement use.

The issuing bodies with recent activity are Seminole County, Florida (a county health procurement) and the Texas Health and Human Services Commission (a state agency). Seminole County posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a community health building in Sanford, Florida, with responses due July 26, 2023 (note the inconsistent date). The Texas HHS Commission issued an RFI on April 3, 2026, to gather vendor information about direct-to-manufacturer prescription programs for self-insured employee and state health plans, with no formal competitive phase or award value identified at that exploratory stage. Geographic activity is limited to Florida and Texas in the recent record. Given the sparse and divergent recent activity, pursue this code only if your firm is actively bidding the Seminole County naloxone opportunity or has specific intelligence that state and local pharmacy procurement is systematically misclassified under this code.